Sentinel lymph node biopsy associated with better quality of life in breast cancer patients

May 02, 2006

Biopsy of the sentinel lymph node, the first lymph node to which fluid from a primary breast tumor drains, was associated with better arm function and better quality of life compared with standard dissection, or removal of lymph nodes in the armpit region in women with early-stage breast cancer, according to a study in the May 3 Journal of the National Cancer Institute. The authors suggest this minimally invasive procedure is a safe and effective alternative to more invasive lymph node dissection and removal.

While patients with invasive breast cancer no longer undergo automatic mastectomy, routine removal of lymph nodes in the armpit region (standard axillary dissection) is still commonly carried out in order to find and take out lymph nodes with cancer in them. However, lymph node removal can cause a number of unpleasant side effects, such as decreased arm and shoulder function. For women with early-stage breast cancer, this type of surgery has little benefit, and some scientists suggest doctors could evaluate breast cancer using a less invasive technique called sentinel lymph node biopsy, where the first lymph node to which fluid from a primary breast tumor drains, is removed and examined.

Robert E. Mansel, of the Wales College of Medicine at Cardiff University in the United Kingdom, and colleagues examined data from 1031 breast cancer patients in the randomized ALMANAC trial, half of whom received sentinel lymph node biopsy followed by lymph node removal, the other half of whom underwent lymph node removal. Data on patients was collected between November 1999 and October 2003.

The authors found that sentinel lymph node biopsy was associated with better arm function, better quality of life, a shorter hospital stay, and faster recommencement of daily activities than standard axillary lymph node dissection. In addition, women who underwent a sentinel lymph node biopsy had a low recurrence rate of cancer and had survival rates equivalent to those of women in the standard treatment group.

The authors write, "This study has shown that sentinel lymph node biopsy is a safe and effective alternative to routine axillary dissection for [lymph node evaluation] in early-stage breast cancer. [...] Our results support the introduction of this minimally invasive staging procedure in operable breast cancer."

In an accompanying editorial, Joseph L. Pater, M.D., and Wendy Parulekar, M.D., of Queen's University in Kingston, Ontario, discuss the strengths and limitations of Mansel and colleagues' study. They question whether the widespread adoption of sentinel lymph node biopsy will need to change once long-term outcome data on relapse-free and overall survival are published. They write, "Given all the information provided, it seems likely that Mansel et al. are correct in concluding that patients obtain benefit from avoiding axillary dissection. However, results of trials with health-related quality-of-life outcomes cannot always be interpreted unambiguously, and more effort is needed to accomplish the goal of having patient-reported outcomes routinely and reliably incorporated into cancer trials."
-end-
Contacts:

Article: Robert Mansel, 44-2920-742749, manselre@cf.ac.uk
Editorial: Nancy Dorrance, 613-533-2869, dorrance@post.queensu.ca

Citations:

Article: Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized Multicenter Trial of Sentinel Node Biopsy versus Standard Axillary Treatment in Operable Breast Cancer: the ALMANAC Trial. J Natl Cancer Inst 2006; 98:599-609.
Editorial: Pater JL, Parulekar W. Sentinel Lymph Node Biopsy in Early Breast Cancer: Has Its Time Come? J Natl Cancer Inst 2006; 98:568-569.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

Journal of the National Cancer Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.